Los Angeles Capital Management
RCUS icon

Los Angeles Capital Management’s Arcus Biosciences RCUS Stock Holding History

Los Angeles Capital Management’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.7K Hold
347
– – ﹤0.01% 1944
2026
Q1 		$7.5K Hold
347
– – ﹤0.01% 2010
2025
Q4 		$7.01K Buy
+347
New +$7.08K ﹤0.01% 2207
2021
Q3 		– Sell
-10,085
Closed -$277K – 1572
2021
Q2 		$277K Sell
10,085
-600
-6% -$17.1K ﹤0.01% 1417
2021
Q1 		$300K Buy
10,685
+2,960
+38% +$103K ﹤0.01% 1435
2020
Q4 		$201K Buy
+7,725
New +$187K ﹤0.01% 1471

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Los Angeles Capital Management's RCUS Position: Q2 2026 in Review

Los Angeles Capital Management held its Arcus Biosciences (RCUS) position steady in Q2 2026 at 347 shares worth $10.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1944.

Los Angeles Capital Management first reported a position in RCUS in Q4 2020 and has held it in 6 quarters since. The position peaked at $300K in Q1 2021. 231 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

  • Los Angeles Capital Management held 347 shares of Arcus Biosciences worth $10.7K as of Q2 2026.
  • Los Angeles Capital Management left its Arcus Biosciences share count unchanged in Q2 2026.
  • Arcus Biosciences made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q2 2026, its #1944 holding.
  • Los Angeles Capital Management first reported a position in Arcus Biosciences in Q4 2020 and has held it in 6 quarters since.
  • Los Angeles Capital Management's Arcus Biosciences position peaked at $300K in Q1 2021.
  • 231 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.